| 中文名 |
培氟沙星
|
| 英文名 |
1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
|
| 中文别名 |
1-乙基-6-氟-1,4-二氢-7-(4-佳绩-哌嗪基)-4-氧代-3-喹啉羧酸
培氟哌酸
1-乙基-1,4-二氢-6-氟-7-(4-甲基-1-哌嗪)-4-氧代-3-喹啉羧酸
1-乙基-6-氟-7-(4-甲基哌嗪基)-4-氧代-1,4-二氢喹啉-3-羧酸
|
| 英文别名 |
MFCD01685696
3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-
PFLX
Abactal
Pefloxacine
Labocton
Silver Pefloxacin
Pefloxacin
1-Ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Pefloxacino
1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Pefloxacin (USAN)
Pefloxacinum
EINECS 274-611-8
|
| 密度 |
1.3±0.1 g/cm3
|
| 沸点 |
529.1±50.0 °C at 760 mmHg
|
| 分子式 |
C17H20FN3O3
|
| 分子量 |
333.357
|
| 闪点 |
273.8±30.1 °C
|
| 精确质量 |
333.148865
|
| PSA |
65.78000
|
| LogP |
1.51
|
| 蒸汽压 |
0.0±1.5 mmHg at 25°C
|
| 折射率 |
1.594
|
| 储存条件 |
2-8℃
|
| 分子结构 |
1、 摩尔折射率:85.63
2、 摩尔体积(cm3/mol):252.4
3、 等张比容(90.2K):679.3
4、 表面张力(dyne/cm):52.4
5、 极化率(10-24cm3):33.94
|
| 计算化学 |
1.疏水参数计算参考值(XlogP):无
2.氢键供体数量:1
3.氢键受体数量:7
4.可旋转化学键数量:3
5.互变异构体数量:无
6.拓扑分子极性表面积64.1
7.重原子数量:24
8.表面电荷:0
9.复杂度:545
10.同位素原子数量:0
11.确定原子立构中心数量:0
12.不确定原子立构中心数量:0
13.确定化学键立构中心数量:0
14.不确定化学键立构中心数量:0
15.共价键单元数量:1
|
| 更多 |
1.性状:类白色晶体。
2.熔点(ºC):270--272
3.溶解性:溶于碱性和酸性溶液,微溶于水。
|
CHEMICAL IDENTIFICATION
-
RTECS NUMBER :
-
VB2002000
-
CHEMICAL NAME :
-
3-Quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-7-(4-methyl-1-piperaziny l)-4-oxo-
-
CAS REGISTRY NUMBER :
-
70458-92-3
-
BEILSTEIN REFERENCE NO. :
-
0567618
-
LAST UPDATED :
-
199806
-
DATA ITEMS CITED :
-
9
-
MOLECULAR FORMULA :
-
C17-H20-F-N3-O3
-
MOLECULAR WEIGHT :
-
333.40
-
WISWESSER LINE NOTATION :
-
T66 BN VVJ B2 DVQ HF I- AT6N DNTJ D1
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Oral
-
SPECIES OBSERVED :
-
Human - man
-
DOSE/DURATION :
-
1714 mg/kg/21W-I
-
TOXIC EFFECTS :
-
Peripheral Nerve and Sensation - paresthesis Peripheral Nerve and Sensation - structural change in nerve or sheath
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Oral
-
SPECIES OBSERVED :
-
Human - man
-
DOSE/DURATION :
-
343 mg/kg/30D-I
-
TOXIC EFFECTS :
-
Musculoskeletal - joints Musculoskeletal - other changes
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intravenous
-
SPECIES OBSERVED :
-
Human - woman
-
DOSE/DURATION :
-
16 mg/kg
-
TOXIC EFFECTS :
-
Behavioral - hallucinations, distorted perceptions Behavioral - muscle contraction or spasticity
-
TYPE OF TEST :
-
LD50 - Lethal dose, 50 percent kill
-
ROUTE OF EXPOSURE :
-
Oral
-
SPECIES OBSERVED :
-
Rodent - mouse
-
DOSE/DURATION :
-
>4 gm/kg
-
TOXIC EFFECTS :
-
Details of toxic effects not reported other than lethal dose value
-
TYPE OF TEST :
-
LD50 - Lethal dose, 50 percent kill
-
ROUTE OF EXPOSURE :
-
Intravenous
-
SPECIES OBSERVED :
-
Rodent - mouse
-
DOSE/DURATION :
-
225 mg/kg
-
TOXIC EFFECTS :
-
Details of toxic effects not reported other than lethal dose value
-
TYPE OF TEST :
-
LD - Lethal dose
-
ROUTE OF EXPOSURE :
-
Oral
-
SPECIES OBSERVED :
-
Mammal - dog
-
DOSE/DURATION :
-
>50 mg/kg
-
TOXIC EFFECTS :
-
Details of toxic effects not reported other than lethal dose value
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Oral
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
7500 mg/kg/30D-C
-
TOXIC EFFECTS :
-
Liver - changes in liver weight Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Oral
-
DOSE :
-
30 gm/kg
-
SEX/DURATION :
-
male 30 day(s) pre-mating
-
TOXIC EFFECTS :
-
Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
MUTATION DATA
-
TYPE OF TEST :
-
Unscheduled DNA synthesis
-
TEST SYSTEM :
-
Rodent - rat Liver
-
DOSE/DURATION :
-
780 umol/L
-
REFERENCE :
-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 221,263,1989
|
方法一:其合成可以诺氟沙星为原料,经甲基化而得产品。
也可以从诺氟沙星中的中间体硼螯合物开始制备。该硼螫合物、乙腈、N- 甲基哌嗪和三乙胺混合,室温反应后再回流。蒸除溶剂,加水,浓盐酸调至Ph=3后再回流。加入活性炭脱色,过滤。滤液碱化至Ph=11,再加活性炭脱色,过滤,用30%醋酸中和至Ph=6.7-7.2,冰箱中过夜。过滤,水洗,干燥得类白色的培氟沙星,收率82%,熔点270-272℃。培氟沙星溶入无水乙醇中,在60~70℃下滴加甲磺酸,反应。冷至15℃,过滤析出的结晶,用10倍乙醇重结晶,得甲磺酸培氟沙星,收率88.5%。
也可硼螯合物、N-甲基哌嗪和三乙胺一起回流。再碱性水解,酸化至Ph=7.2,得培氟沙星;将其加入甲磺酸的水溶液中,反应得到的粗品用85%乙醇重结晶,得甲磺酸培氟沙星,收率79.4%,熔点284℃。
本网页内容来自不同专业数据源,如对内容有疑义,欢迎联系service1@chemsrc.com。